Research on the effectiveness, safety and effective protection time of novel coronavirus pneumonia (COVID-19) vaccines

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100045353

Enrollment

Unknown

Registered

2021-04-13

Start date

2021-05-01

Completion date

Unknown

Last updated

2021-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Case series:SARS-CoV-2 inactivated vaccine

Eligibility

Sex/Gender

All

Age

12 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Healthy subjects aged 12-80 years; 2. Male or non-pregnant female; 3. No history of SARS-CoV-2 infection.

Exclusion criteria

Exclusion criteria: 1. Subjects who are allergic to any component of the vaccine, and those who had allergic reactions when received same type of vaccine in the past; 2. Subjects who have had severe allergic reactions to vaccines in the past (such as acute allergic reactions, angioedema, and dyspnea); 3. Subjects who have uncontrolled epilepsy, or other severe neurological diseases; 4. Subjects who are suffering from a fever, or acute diseases, or acute exacerbation of chronic diseases, or uncontrolled severe chronic diseases; 5. Subjects who are unable to complete the one-year follow-up.

Design outcomes

Primary

Measure	Time frame
SARS-CoV-2 related antibodies;	—

Countries

China

Contacts

Public ContactChen Gang

Fujian Provincial Hospital

chengangfj@163.com+86 13509337027

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026